US Court Dismisses Lawsuit Against Emcure Over Covid-19 Vaccine
A US court dismissed a lawsuit filed by HDT Bio Corp against Emcure Pharmaceuticals regarding Covid-19 vaccine technology. The court ruled in favor of Emcure, rejecting HDT's claims of non-payment of royalties and stolen technology.
New Delhi, Dec 5 (PTI) A US Court has dismissed a lawsuit filed by HDT Bio Corp against Pune-based Emcure Pharmaceuticals.
A Federal court in Seattle, Washington, has dismissed the lawsuit lawsuit filed by HDT against Emcure regarding Covid-19 vaccine technology.
HDT had named Emcure as a party in the suit, alleging non-payment of royalties and demanded a compensation of at least USD 950 million.
When contacted a company spokesperson said, "The ruling vindicates our stand".
Emcure had contended in the court that the lawsuit was illegitimate and brought by HDT to compensate for its business shortcomings.
HDT Bio had alleged that the Pune-based firm had stolen its vaccine technology which it had licensed to Gennova for manufacture and distribution in India.
A Federal court in Seattle, Washington, has dismissed the lawsuit lawsuit filed by HDT against Emcure regarding Covid-19 vaccine technology.
HDT had named Emcure as a party in the suit, alleging non-payment of royalties and demanded a compensation of at least USD 950 million.
When contacted a company spokesperson said, "The ruling vindicates our stand".
Emcure had contended in the court that the lawsuit was illegitimate and brought by HDT to compensate for its business shortcomings.
HDT Bio had alleged that the Pune-based firm had stolen its vaccine technology which it had licensed to Gennova for manufacture and distribution in India.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- KBC Global
- 0.58 ( -9.38)
- 75496759
- Enbee Trade & Fi
- 0.94 (+ 4.44)
- 51176636
- Vodafone Idea L
- 6.56 ( -0.76)
- 38744095
- Pradhin
- 0.37 (+ 8.82)
- 37543784
- Sunshine Capital
- 0.37 (+ 2.78)
- 28170643
MORE NEWS
© 2025 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback